Neuro fibrillary tangles are formed by the aggregation of tau protein which ultimately results in the death of neuron, and beta amyloid is formed by the cleavage of beta secretase.
Here what happened to the synthesis of alpha secretase, in Alzheimer's patient is there any competition between alpha secretase and beta secretase or alpha secretase is completely absent ?
Alpha secretase levels are reduced in AD brain and beta secretase levels are increased by many folds. You can check the reference in link for further information
http://www.ncbi.nlm.nih.gov/pubmed/12445809
Edible and medicinal mushrooms show potential to mitigate neurodegenerative diseasesEdible and medicinal mushrooms show potential to mitigate neurodegenerative diseases
Certain edible and medicinal mushrooms contain bioactive compounds that may enhance nerve growth in the brain and protect against neurotoxic stimuli such as inflammation that contribute to neurodegenerative diseases like dementia and Alzheimer's disease.
Finally, a Winner for Alzheimer's? Anti-amyloid Agent Shows Promise
Pauline Anderson
July 26, 2018
- 11Read Comments
- Add to Email Alerts
CHICAGO — Positive results for an anti-amyloid agent in patients with early-stage Alzheimer's disease (AD) is drawing praise, but experts are calling for caution.
Results from the new phase 2 study showed a statistically significant reduction in brain amyloid with a high dose of BAN2401 (Eisai Co. Ltd/Biogen Inc) at 18 months.
In addition, the study showed a dose-dependent, statistically significant, and clinically meaningful slower decline in cognition and function with the highest dose compared to placebo.
"This is the first large clinical trial to support the amyloid hypothesis," Lynn D. Kramer, MD, chief clinical officer and chief medical officer, Neurology Business Group, Eisai Co, Inc, told a press briefing.
The study was released here at the Alzheimer's Association International Conference (AAIC) 2018.
Unique Trial Design
The multicenter study included 856 patients with early AD (mild cognitive impairment due to AD or mild AD dementia) and amyloid pathology confirmed by positron-emission tomography (PET) or cerebral spinal fluid (CSF) tracer.
At baseline, the mean Mini‒Mental State Examination score was 25.6; the mean Clinical Dementia Rating Scale‒Sum of Boxes (CDR-SB) score was 2.9, and the mean Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) score was 22.2.
- Badges
- Science topic
- Similar topics
- Organizational Psychology
- Training